Company intelligence / Profile preview

Aptadel Therapeutics

Barcelona, Catalonia, Spainaptadeltx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Aptadel Therapeutics is a pre-clinical stage biotech developing an RNA aptamer-based platform to deliver various therapeutic agents—including siRNAs, miRNAs, chemotherapeutic drugs, and small molecules—directly into cancer cells. Their lead program targets Ewing Sarcoma using an EphA2-targeting approach. No clinical results have been reported as of May 2025.

Therapeutic areas: OncologyHematology
Modalities: RNA aptamerssiRNA conjugatesmiRNA conjugatesChemotherapeutic drug conjugatesSmall molecule delivery via aptamer platform
Industry: Biotech

Drug pipeline

7 assets

ADEL-001

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

Spin-off from IDIBELL (Institut d’Investigació Biomèdica de Bellvitge)Co-founded by Fundación Alba

Beyond the preview

Go deeper on Aptadel Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aptadel Therapeutics.

Explore the full profile